Potenza Therapeutics, Inc.

Surface Oncology, Inc.

Five Prime Therapeutics, Inc.

Nels P Nielson

Daniel Hicklin

William Winston

Cynthia Seidel-Dugan

Heather R Brodkin

Jose-Andres Salmeron-Garcia

Bianka Prinz

Scott C Chappel

Pamela M Holland

Andrew Lake

Matthew Rausch

Michael Warren

Austin Dulak

Erik Devereaux

Tauqeer Zaidi

Sonia Das

David Bellovin

Kathy Miller

Maike Schmidt

Luis Borges

Majid Ghoddusi

Charles Kaplan

Derrick Houser

Gloria Brattich

Cynthia S Dugan

Felicia Kemp

Philipp Steiner

Sonja Kleffel

Christopher James Nirschl

Alison M O'Neill

Cynthia Seidel-dugan

Heather Brodkin

The present disclosure provides antibodies and antigen-binding fragments thereof that specifically bind to human B7-H4 (and optionally cynomolgus monkey, mouse, and/or rat B7-H4) and compositions comprising such antibodies or antigen-binding fragments thereof. In a specific aspect, the antibodies or antigen-binding fragments thereof that specifically bind to human B7-H4 increase T cell proliferation, increase interferon-gamma production, and/or deplete B7-H4 expressing cells via ADCC activity. The present disclosure also provides methods for treating disorders, such as cancer, by administering an antibody or antigen-binding fragment thereof that specifically binds to human B7-H4.

B7-H4 antibodies and methods of use thereof

The invention provides anti-CD39 antibody compositions and their use in treating cancer.

Anti-CD39 antibody compositions and methods

Provided herein are antigen-binding proteins (ABPs) that selectively bind to TIGIT and its isoforms and homologs, and compositions comprising the ABPs. Also provided are methods of using the ABPs, such as therapeutic and diagnostic methods.

Anti-TIGIT antigen-binding proteins and methods of uses thereof

Anti-TIGIT antigen-binding proteins and methods of use thereof

Provided herein are antibodies, or antigen binding fragments thereof, that selectively bind to NRP-1 and its isoforms and homologs, and compositions comprising the antibodies, or antigen binding fragments thereof. Also provided are methods of using the antibodies, or antigen binding fragments thereof, such as therapeutic and diagnostic methods.

Anti-neuropilin antigen-binding proteins and methods of use thereof

Provided herein are antigen-binding proteins (ABPs) that selectively bind to GITR and its isoforms and homologs, and compositions comprising the ABPs. Also provided are methods of using the ABPs, such as therapeutic and diagnostic methods.

Anti-GITR antigen-binding proteins and methods of use thereof

The present disclosure relates to anti-CD39 antibodies, and antigen binding portions thereof and their use in treating cancer.

Antibodies that bind CD39 and uses thereof

Provided herein are antigen-binding proteins (ABPs) that selectively bind to NRP-1 and its isoforms and homologs, and compositions comprising the ABPs. Also provided are methods of using the ABPs, such as therapeutic and diagnostic methods.

Growing community of inventors

Lebanon, NH, United States of America

Nels P Nielson